Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [IGX7032] to CXCR4 - BSA and Azide free
- Suitable for: Flow Cyt, Functional Studies
- Reacts with: Human
Product nameAnti-CXCR4 antibody [IGX7032] - BSA and Azide free
See all CXCR4 primary antibodies
DescriptionRabbit monoclonal [IGX7032] to CXCR4 - BSA and Azide free
Tested applicationsSuitable for: Flow Cyt, Functional Studiesmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Human
Recombinant fragment. This information is considered to be commercially sensitive.
- Flow Cyt: Jurkat cells.
This product was made using synthetic libraries and phage display technology.
This antibody is a recombinant chimeric antibody. Rabbit chimeric monoclonal antibody (Human Fab/ Rabbit Fc).
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferConstituent: 100% PBS
Concentration information loading...
- Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077)
- Goat Anti-Rabbit IgG H&L (Alexa Fluor® 555) (ab150078)
- Goat Anti-Rabbit IgG H&L (Alexa Fluor® 647) (ab150079)
- Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) (ab150080)
- Goat Anti-Rabbit IgG H&L (HRP) (ab205718)
- Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed (ab96899)
Our Abpromise guarantee covers the use of ab277509 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
FunctionReceptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ions levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiquitin; leading to enhance intracellular calcium ions and reduce cellular cAMP levels. Involved in haematopoiesis and in cardiac ventricular septum formation. Plays also an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Could be involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 X4 isolates and as a primary receptor for some HIV-2 isolates. Promotes Env-mediated fusion of the virus.
Tissue specificityExpressed in numerous tissues, such as peripheral blood leukocytes, spleen, thymus, spinal cord, heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, cerebellum, cerebral cortex and medulla (in microglia as well as in astrocytes), brain microvascular, coronary artery and umbilical cord endothelial cells. Isoform 1 is predominant in all tissues tested.
Involvement in diseaseDefects in CXCR4 are a cause of WHIM syndrome (WHIM) [MIM:193670]; also known as warts, hypogammaglobulinemia, infections and myelokathexis. WHIM syndrome is an immunodeficiency disease characterized by neutropenia, hypogammaglobulinemia and extensive human papillomavirus (HPV) infection. Despite the peripheral neutropenia, bone marrow aspirates from affected individuals contain abundant mature myeloid cells, a condition termed myelokathexis.
Sequence similaritiesBelongs to the G-protein coupled receptor 1 family.
DomainThe amino-terminus is critical for ligand binding. Residues in all four extracellular regions contribute to HIV-1 coreceptor activity.
modificationsPhosphorylated on agonist stimulation. Rapidly phosphorylated on serine and threonine residues in the C-terminal. Phosphorylation at Ser-324 and Ser-325 leads to recruitment of ITCH, ubiquitination and protein degradation.
Ubiquitinated by ITCH at the cell membrane on agonist stimulation. The ubiquitin-dependent mechanism, endosomal sorting complex required for transport (ESCRT), then targets CXCR4 for lysosomal degradation. This process is dependent also on prior Ser-/Thr-phosphorylation in the C-terminal of CXCR4. Also binding of ARRB1 to STAM negatively regulates CXCR4 sorting to lysosomes though modulating ubiquitination of SFR5S.
Sulfation on Tyr-21 is required for efficient binding of CXCL12/SDF-1alpha and promotes its dimerization.
O- and N-glycosylated. Asn-11 is the principal site of N-glycosylation. There appears to be very little or no glycosylation on Asn-176. N-glycosylation masks coreceptor function in both X4 and R5 laboratory-adapted and primary HIV-1 strains through inhibiting interaction with their Env glycoproteins. The O-glycosylation chondroitin sulfate attachment does not affect interaction with CXCL12/SDF-1alpha nor its coreceptor activity.
Cellular localizationCell membrane. In unstimulated cells, diffuse pattern on plasma membrane. On agonist stimulation, colocalizes with ITCH at the plasma membrane where it becomes ubiquitinated.
- Information by UniProt
- C-X-C chemokine receptor type 4 antibody
- CD184 antibody
- CD184 antigen antibody
Flow cytometric analysis of HEK-293T (Human embryonic kidney epithelial cell, Left) / Jurkat (Human T cell leukemia T lymphocyte, Right) cells labeling CXCR4 with ab277509 at 1/50 dilution (Red) compared with a Rabbit monoclonal IgG (ab172730) (Black) and cell without incubation with primary antibody and secondary antibody (Blue). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077), at 1/2000 dilution was used as the secondary antibody.
Negative control: HEK-293T cells.
A calcium dose-response assay was performed at Multispan Inc. (Hayward, CA) following their MULTISCREEN™ Calcium 1.0 No Wash Assay Kit protocol. Target overexpressing cells were seeded in a 384 well plate in HHBS buffer at a density between 3,000 to 9,000 cells/well. Cells were incubated with calcium buffer containing Fluo-8 loading dye and probenecid (supplied in the kit). To test for agonist activity, cells were injected with a known control agonist in the 19th second of incubation and calcium mobilization was monitored for a total of 180 seconds. Following a 15-minute rest period, the cells from agonist mode testing were treated with the same known control agonist, in the 19th second, and calcium mobilization was again monitored as outlined above to assay for antagonist activity. Fluorescent emissions were read at 525 nm with excitation at 490 nm in a FLIPR384 instrument (Molecular Devices). Data analysis and antibody figures were prepared utilizing GraphPad Prism 8.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab277509 has not yet been referenced specifically in any publications.